Lung cancer drug Imfinzi improves overall survival at interim analysis in phase III CASPIAN trial

This article was originally published here

A planned interim analysis conducted by an Independent Data Monitoring Committee concluded that the trial has met its primary endpoint by showing a statistically-significant and clinically-meaningful improvement in OS

The post Lung cancer drug Imfinzi improves overall survival at interim analysis in phase III CASPIAN trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply